Desferrioxamine as immunomodulatory agent during microorganism infection

Current Pharmaceutical Design

Volumn 15, Issue 11, 2009, Pages 1261-1268

  Williams, A ^a   Meyer, D ^b  

^a UNIVERSITY OF JOHANNESBURG   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Desferrioxamine; HIV; Immune restoration; Immunomodulatory; Iron; M.tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; CYTOKINE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRIOXAMINE; IMMUNOMODULATING AGENT;

ANTIBODY SPECIFICITY; ANTIVIRAL ACTIVITY; CELLULAR IMMUNITY; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST PATHOGEN INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROPHILICITY; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IRON CHELATION; IRON OVERLOAD; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TH1 CELL; TH2 CELL; TUBERCULOSIS;

ANIMALS; COMMUNICABLE DISEASES; CYTOKINES; DEFEROXAMINE; HUMANS; IMMUNOLOGIC FACTORS; IRON CHELATING AGENTS;

EID: 65649141602     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209787846801     Document Type: Review

References (79)

1. Meyer D. Iron Chelation as therapy for HIV and Mycobaterium tuberculosis Co-infection under conditions of iron overload. Curr Pharm Des 2006; 12: 1943-7.
2. Marx JJM. Iron and Infection: competition between host and microbes for a precious element. Best Pract Res Clin Haematol 2002; 15(2): 411-26.
3. Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996; 5: 36-46.
4. Simonart T. Iron: a target for the management of Kaposi's sarcoma? BMC Cancer 2004; 4: 1-9.
5. Tam TF, Leung-Toung R, Li W, Wang Y, Karimian K, Spino M. Iron chelator research: Past, present and future. Curr Med Chem 2003; 10(12): 983-95.
6. Traoré HN, Meyer D. The effect of iron overload on in vitro HIV-1 infection. J Clin Virol 2004; 31S: S92-8.
7. Weinberg ED. Iron loading and disease surveillance. Emerg Infect Dis 1999; 5(3): 346-52.
8. Cinatl J, Scholz M, Weber B, Cinad J, Rabenau H, Markus BH, et al. Effects of Desferrioxamine on human cytomegalovirus replication and expression of HLA antigens and adhesion molecules in human vascular endothelial cells. Transpl Immuno 1995; 3: 313-20.
9. Cronjé L, Bornman L. Iron Overload and Tuberculosis: a case for iron chelation therapy. Int J Tuberc Lung Dis 2005; 9(1): 2-9.
10. Cronjé L, Edmondson N, Eisenach KD, Bornman L. Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions. FEMS Immunol Med Microbiol. 2005; 45: 103-12.
11. Dam T. Siderophores-potential candidate in the therapy of neonatal meningitis. J Med Microbiol 2005; 54(6): 613-13.
12. Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HSLM, Marx JJM, van Asbeck BS. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by iron chelators Deferoxamine, Deferiprone, and Bleomycin. Infectious Diseases Society of America. J Infect Dis 2000; 181: 484-90.
13. Gomes MS, Dom G, Pedrosa J, Boelaert JP, Appelberg A. Effects of iron deprivation on Mycobacterium avium growth. Tuber Lung Dis 1999; 79(5):321-8.
14. Lounis N, Truffot-Pernot C, Grosset J, Gordeuk VR, Boelaert JR. Iron and Mycobaterium tuberculosis infection. Elsevier Science B.V. J Clin Virol 2001; 20: 123-6.
15. Mabeza GF, Loyevsky M, Gordeuk VR, Weiss G. Iron chelation therapy for malaria: a review. Pharmacol Ther 1999; 81(1): 53-75.
16. Martelius T, Scholz K Krogerus L, H6ckerstedt K, Loginov R, Bruggeman C, et al. Antiviral and immunomodulatory effects of Desferrioxamine in Cytomegalovirus-infected rat liver allografts with rejection. Transplantation 1999; 68(11): 1753-61.
17. Ratledge C. Iron, Mycobacteria and Tuberculosis. Elsevier Ltd. Tuberculosis 2004; 84: 110-30.
18. Rotheneder A, Fritsche G, Heinisch L, Mollmann U, Heggemann S, Larcher C, et al. Effects of Synthetic sidephores on proliferation of Plasmodium falciparum in infected human erythrocytes. Antimicrob Agents Chemother 2002; 46(6): 2010-13.
19. Schaible UE, Collins HL, Priem F, Kaufmann SHE. Correction of the iron overload defect in β-2-microglobulin knockout mice by lactoferrin abolishes their increased susceptibility to tuberculosis. J Exp Med 2002; 196: 1507-13.
20. van Asbeck BS, Georgiou NA, van Bruggen T, Oudshoorn M, Nottet HSLM, Marx JJM. Anti -HIV effect of iron chelators: different mechanisms involved. J Clin Virol 2001; 20:141-7.
21. Weinberg GA. Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob Agents Chemother 1994; 38: 997-1003.
22. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 1964; 119 (2): 758-69.
23. Pootrakul P. Iron Chelators. Bangkok, Thailand. October 24-28, 1999; accessed from http://ishapd.org/1999/28.pdf on 25/9/2007.
24. Xiao L. Desferrioxamine (DFO). Free Radic Biol Med 2003; 77:222-32.
25. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology 2004; 2004(1): 14-34.
26. Boelaert JR, Gordeuk VR, Piette J, Weinberg, G.A. Conference report: International Conference on HIV and Iron, Brugge 1997.Blackwell Science Limited. Trop Med Int Health 1997; 2: 1102-06.
27. Gordeuk VR, McLaen CE, MacPhail AP, Deichsel G, Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and Tuberculosis: Strachan's 1929 Thesis Revisited. Blood 1996; 87(8): 3470-6.
28. Moyo VM, Gangaidzo IT, Gordeuk VR, Kiire CF, Macphail AP. Tuberculosis and iron overload in Africa: a review. Cent Afr J Med 1997; 43(11): 334-9.
29. Siah CW, Trinder D, Olynyk JK. Iron Overload. Clin Chim Acta 2005; 358: 24-36.
30. Walker ARP, Segal I. Iron Overload in Sub-Saharan Africa: to what extent is it a public health problem? Br J Nutr 1999; 81: 427-34.
31. Boelaert JR, Piette J. The potential negative role of iron in HIV infection and its implications. Inabis. 2000; 1-7.
32. Crichton RR, Ward RJ. An overview of Iron Metabolism: molecular and cellular criteria for the selection of iron chelators. Curr Med Chem 2003: 10(12): 997-1004.
33. Wood J. The mechanisms and clinical sequelae of cardiac iron overload. Novartis Oncology 2005; 1-16.
34. Chitambar CR. Cellular iron metabolism: mitochondria in the spot-light. Blood 2005; 105(5): 1844-5.
35. Niihara Y, Ge J, Shalev O, Wu H, Tu A, Tanaka KR. Desferrioxamine decreases NAD redox potential of intact red blood cells: evidence for desferrioxamine as an inducer of oxidant stress in red blood cells. BMC Clin Pharmacol 2002; 2: 8-11.
36. Padhye U. Excess Dietary iron is the root cause for increase in childhood autism and allergies. Med Hypotheses 2003; 61(2): 220-2.
37. Weiss G, Wachter H, Fuchs D. Linkage of cell-mediated immunity to iron metabolism. Immunol Today 1995; 16(10): 495-500.
38. Lee H-W, Lee J, Lee S-K, Lee S-K, Kim E-C. Differential regulation of iron chelator-induced IL-8 synthesis via MAP kinase and NF-κB in immortalized and malignant oral keratinocytes. BMC Cancer 2007; 7: 176-87.
39. Harhaji L, Vuckovic O, Miljkovic D, Stosic-Grujicic S, Trajkovic V. Iron down regulates macrophage anti-tumor activity by blocking nitric oxide production. Clin Exp Immunol 2004; 137: 109-16.
40. Del Vecchio GC, Schettini F, Piacente L, De Santis A, Giordano P, De Mattia D. Effects of Deferiprone on immune status and cytokine pattern in thalassaemia major. Acta Haematol 2002; 108: 144-9.
41. Walker EM, Walker SM. Review: Effects of Iron Overload on the Immune System. Ann Clin Lab Sci 2000; 30(4): 354-65.
42. Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, et al. Oxidative stress and inflammation in iron-overloaded patients with β-thalassaemia or sickle cell disease. Br J Haematol 2006; 135: 254-63.
43. Gordeuk VR, Ballou S, Lozanski G, Brittenham GM. Decreased concentrations of Tumor Necrosis Factor-alpha in supernatants of monocytes from homozygotes for hereditary hemochromatosis. Blood 1992; 79: 1855-60.
44. Mencacci A, Cenci E, Boelaert JR, Bucci P, Mosci P, Fé d'Ostiani C, et al. Iron overload alters innate and T-helper cell response to Candida albicans in mice. J Infect Dis 1997; 175: 1467-76.
45. Miller S. Beyond the CD4 cell count. The Clinician's Guide to the immunity of HIV infection. Beckman Coulter Inc. 2002; 3, 7, 19-23, 27.
46. Ates Ö, Musellim B, Ongen G, Topal-Sarikaya A. Interleukin-10 and Tumor Necrosis Factor-α gene polymorphisms in Tuberculosis. J Clin Immunol 2007; doi 10.1007/s10875-007-9155-2.
47. Bal AM, Lakhashe SK, Thakar MR, Tripathy SP, Paranjape RS. Dysregulation of proinflammatory and regulatory cytokines in HIV infected persons with active tuberculosis. Cytokine 2005; 30: 275-81.
48. Oh M, Kang C, Kim U, Kim NJ, Lee B, Kim HB, et al. Cytokine responses induced by Mycobacterium tuberculosis in patients with HIV-1 infection and tuberculosis. Elsevier Ltd. Int J Infect Dis 2005; 9: 110-16.
49. Meddows-Taylor S, Martin DJ, Tiemessen CT. Dysregulated production of Interleukin-8 in individuals infected with Human Immunodeficiency Virus Type 1 and Mycobacterium tuberculosis. Infect Immun 1999; 67(3): 1251-60.
50. Bennett S, Breit SN. Variables in the isolation and culture of human monocytes that are of particular relevance to studies of HIV. J Leukoc Biol 1994; 56: 236-40.
51. Losikoff P, Fichorova R, Snyder B, Rodriguez I, Cu-Uvin S, Harwell J, et al. Genital Tract Interleukin-8 but not Interleukin-1β or Interleukin-6 concentration is associated with bacterial vaginosis and its clearance in HIV-infected and HIV-uninfected Women. Infect Dis Obstet Gynecol 2007; 2007: 1-6.
52. Roth M, Block LH. Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines. Thorax 2000; 55: 678-84.
53. Verbon A, Juffermans N, van Deventer SJH, Speelman P, van Deutekom H, van der Poll T. Serum concentrations of cytokines in patients with active Tuberculosis (TB) and after treatment. Clin Exp Immunol 1999; 115: 110-3.
54. Agarwal SK, Marshall Jr GD. In vivo alteration in type-1 and type-2 cytokine balance: a possible mechanism for elevated Total IgE in HIV-infected patients. Hum Immunol 1998; 59:99-105.
55. Kedzierska K, Crowe SM, Turville S, Cunningham AL. The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages. Rev Med Virol 2003; 13: 39-56.
56. Lane BR, Lore KL, Bock PJ, Andersson J, Coffey MJ, Strieter RM, et al. Interleukin-8 stimulates Human Immunodeficiency Virus Type 1 replication and is a potential new target for antiretroviral therapy. J Virol 2001; 75(17): 8195-202.
57. Zhang Y, Broser M, Cohen H, Bodkin M, Law K, Reibman J, et al. Enhanced Interleukin-8 release and gene expression in macrophages after exposure to Mycobacterium tuberculosis and its components. J Clin Invest 1995; 95: 586-92.
58. Alfano M, Poli, G. The cytokine Network in HIV infection. Curr Mol Med 2002; 2: 677-89.
59. Golenser J, Domb A, Mordechai-Daniel T, Leshem B, Luty A, Kremsner P. Iron Chelators: correlation between effects on Plasmodium spp. and immune functions. J Parasitol 2006; 92(1): 170-7.
60. Schubert S, Autenrieth IB. Conjugation of Hydroxyethyl Starch to Desferrioxamine (DFO) modulates the dual role of DFO in Yersinia enterocolittica infection. Clin Diagn Lab Immunol 2000; 7(3): 457-62.
61. Bradley B, Prowse SJ, Bauling P, Lafferty KJ. Desferrioxamine treatment prevents chronic islet allograft damage. Diabetes 1986; 35(5): 550-5.
62. Lipsky JJ, Lietman PS. Iron and Deferoxamine in lymphocyte blastogenesis. J Immunopharmacol 1980; 2(2): 179-87.
63. Polson RJ, Jenkins R, Lombard M, Williams AC, Roberts S, Nouri-Aria K, et al. Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology 1990; 71: 176-81.
64. Scholz M, Blaheta RA, Henrich D, Cinatl J, Markus BH, Doerr HW, et al. Immunomodulatory properties of the metal chelators Desferrioxamine and Diethylenetriamine penta-acetic acid in vitro. Transplantation 1996; 62(9): 1371-4.
65. Carotenuto P, Pontesilli O, Cambier JC, Hayward AR. Desferoxamine blocks IL 2 expression on human T lymphocytes. J Immunol 1986; 136(7): 2342-7.
66. Weinberg K, Champagne J, Lenarsky C, et al. Desferrioxamine (DFO) inhibition of interleukin 2 receptor (IL2) expression: therapy of graft versus host disease (GVHD). Blood 1986; 68: 286.
67. Autenrieth IB, Bohn E, Ewald JH, Heesemann J. Deferoxamine B but not deferoxamine G1 inhibits cytokine production in murine bone marrow macrophages. J Infect Dis 1995; 172: 490-6.
68. Markel TA, Crisostomo PR, Wang M, Herring CM, Lahm T, Meldrum KK, et al. Iron chelation acutely stimulates fetal human intestinal cell production of IL-6 and VEGF while decreasing HGF: the roles of p38, ERK, and JNK MAPK signaling. Am J Physiol Gastrointest Liver Physiol 2007; 292: G958-63.
69. Aucella F, Vigilante M, Scalzulli P, Musto P, Crisetti A, Modoni S, et al. Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 1194-9.
70. Okada T, Sawada T, Kubota K. Deferoxamine enhances antiproliferative effect of interferon-γ against hepatocellular carcinoma cells. Cancer Lett 2007; 248: 24-31.
71. Bergeron RJ, Wiegand J, Brittenham GM. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood 2002; 99: 3019-26.
72. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the Antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of Triapine compared with Desferrioxamine and the potent Pyridoxal Isonicotinoyl Hydrazone Analogue 311. Clin Cancer Res 2003; 9: 402-14.
73. Sangchot P, Sharma S, Chetsaweng B, Porter J, Govitrapong P, Ebadi M. Deferoxamine Attenuates Iron-induced oxidative stress and prevents mitochondrial aggregation and α- Synuclein Translocation in SK-N-SH cells in Culture. Dev Neurosci 2002; 24: 143-53.
74. Traoré HN, Meyer D. Comparing qualitative and quantitative spectroscopic techniques for the detection of the effect of direct iron loading of mammalian cell cultures. Methods Cell Sci 2002; 23: 175-84.
75. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF. Deferiprone (L1) chelates pathological iron deposits from membranes of intact Thalassemic and Sickle Red Blood Cells both In Vitro and In vivo. Blood 1995; 86(5): 2008-13.
76. Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZL. The antimalarial action of Desferal involves a direct access route to Erythrocytic (Plasmodium falciparum) parasites. J Clin Invest 1993; 91: 218-24.
77. Williams A. MSc dissertation entitled "Improving the Functionality of Infected, Iron Loaded Mammalian Cells through the Use of DFO in an In Vitro Protocol". Document held at The University of Johannesburg Library, accepted April 2008; 1-100.
78. Bergeron RJ, Wiegand J, Brittenham GM. HBED: A potential alternative to Deferoxamine for Iron-Chelating Therapy. Blood 1998; 91: 1446-52.
79. Reeves G, Todd I. Lecture Notes on Immunology. 3rd edition. Blackwell Science. 1996; 3-18; 68-76.